Table 3.

Completed clinical trials with studies relative to AMPs.

Trial Number	Phase	Results	Reference
NCT01959113	1	AMPs secreted by commensal coagulase-negative Staphylococcus in healthy skin displayed selectively antimicrobial activity against S. aureus.	[148]
NCT01967628	1	Supplementation of vitamin D3 during increased AMP (e.g., LL-37) concentration in airway surface liquid in the Winter and Spring seasons.	[149]
NCT01372995	2	Treatment with a high-dose vitamin D3 can increase the expression of human cationic antimicrobial protein (hCAP18) mRNA in plasma.	[150]
NCT01447017 NCT01522391	2	DPK 060, an antimicrobial peptide derived from the endogenous protein kininogen, was an effective and safe drug candidate for the topical treatment of microbial infections.	[151]
NCT02456480	2	Treatment with topical omiganan, an indolicidin analog, significantly improved the local objective scoring atopic dermatitis index in patients.	[152]
ISRCTN12149720	2	Treatment of anti-biofilm peptide P60.4Ac-containing ototopical drops was safe and well-tolerated, with 47% of successful cases for patients suffering from chronic suppurative otitis media.	[153]
IRCT20090822002365N17	3	Supplementation of CoQ10 dramatically increased serum levels of cathelicidin LL-37.	[154]
ChiCTR-OIC-16010250	3	Nal-P-113, an AMP P-113 with histidine residues replaced by β-naphthylalanine, can restrain the growth of Streptococcus gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis and biofilm formation at a concentration of 20 μg/mL.	[155]
NCT00310726	None	Polymorphisms in the human β-defensin 1 gene were negatively and significantly associated with HIV-1 infection in the Zambian population.	[156]
NCT03622918	None	The colistin/rifampicin combination treatment induced a higher microbiological response rate in patients with pneumonia induced by colistin-resistant Acinetobacter baumannii.	[157]